DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Podrobná bibliografie
Hlavní autoři:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Médium:	Journal article
Jazyk:	English
Vydáno:	Oxford University Press 2014

Podobné jednotky

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
Autor: Gupta, A, a další
Vydáno: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Autor: Gupta, A, a další
Vydáno: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
Autor: Robert, C, a další
Vydáno: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Autor: Robert, C, a další
Vydáno: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Autor: Kirkwood, J, a další
Vydáno: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Autor: Flaherty, K, a další
Vydáno: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
Autor: K. Haslett, a další
Vydáno: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Autor: Edmund Poon, a další
Vydáno: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Autor: Jessie Villanueva, a další
Vydáno: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
Autor: Paolo A. Ascierto, a další
Vydáno: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
Autor: Eva Marie Erfurth, a další
Vydáno: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
Autor: Andrea Gazzin, a další
Vydáno: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
Autor: Tahar Sif eddine Bouchema, a další
Vydáno: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Autor: Pacey, S, a další
Vydáno: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
Autor: Anne L Estep, a další
Vydáno: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Autor: Sara Bjursten, a další
Vydáno: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Autor: Sarah J. Welsh, a další
Vydáno: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
Autor: Blessie Elizabeth Nelson, a další
Vydáno: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
Autor: Sarit Cohen‐Rabbie, a další
Vydáno: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
Autor: Hui-Ju Huang, a další
Vydáno: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Autor: Leijen, S, a další
Vydáno: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Autor: Leijen, S, a další
Vydáno: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
Autor: Bengt Tholander, a další
Vydáno: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Autor: Ken Saijo, a další
Vydáno: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
Autor: Anaïs Roeser, a další
Vydáno: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
Autor: Lovisa Falkman, a další
Vydáno: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
Autor: Clare Judith Stones, a další
Vydáno: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Autor: Jan Leipe, a další
Vydáno: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
Autor: Matthew R. Kroll, a další
Vydáno: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
Autor: Shivshankari Rajkumar, a další
Vydáno: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
Autor: J. Steininger, a další
Vydáno: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
Autor: I. V. Samoylenko, a další
Vydáno: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
Autor: B. Ziółkowska, a další
Vydáno: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Autor: Michael J. Vido, a další
Vydáno: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Autor: Zeynep Eroglu, a další
Vydáno: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
Autor: Raphael Reinhard, MD, a další
Vydáno: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
Autor: Manrose Singh, a další
Vydáno: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
Autor: Sivakamavalli Jeyachandran
Vydáno: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
Autor: Ariane Fizazi, a další
Vydáno: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
Autor: Marit A. C. Vermunt, a další
Vydáno: (2021-08-01)